Mengyuan Hu
Overview
Explore the profile of Mengyuan Hu including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
22
Citations
70
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Zhang L, Yan H, Sun H, Hu M
Sci Rep
. 2025 Mar;
15(1):8904.
PMID: 40087300
In order to study the impact of periodic loads on the vibration performance of the flexible positioning platform in the key mechanisms of the ultra-high acceleration macro-micro motion platform, and...
2.
Yang F, Hu M, Xu L, Zheng X, Zhu L, Zhang L, et al.
BMC Gastroenterol
. 2025 Jan;
25(1):28.
PMID: 39844086
Background: While the associations between pediatric non-obese metabolic dysfunction-associated fatty liver disease (MAFLD) and multiple diagnostic biomarkers are well-established, the role of a broader range of blood-based, urine-based, and body...
3.
Meng Y, Yao Z, Ke X, Hu M, Ren H, Gao S, et al.
J Control Release
. 2024 Dec;
378:438-459.
PMID: 39667569
Cancer vaccines are promising therapeutic approaches to enhance specific T-cell immunity against most solid tumors. By stimulating anti-tumor immunity, clearing minimal residual disease, and minimizing adverse effects, these vaccines target...
4.
Yang F, Hu M, Zhang H, Zheng X, Chen L, Zhu L, et al.
Diabetes Metab Syndr Obes
. 2024 Dec;
17:4627-4639.
PMID: 39649758
Background: Metabolic-associated steatotic liver disease (MASLD) is a novel term proposed in 2023 to replace non-alcoholic fatty liver disease (NAFLD) with the aim of better reflecting its pathogenesis and clinical...
5.
Hu M, Hu W, Zhang Z
Am J Clin Exp Immunol
. 2024 Nov;
13(5):233-235.
PMID: 39583341
In recent years, complex interactions between intratumoral bacteria and neutrophils have been identified as significant factors in tumor occurrence and development. This commentary synthesizes findings from the past five years...
6.
Yuan F, Han X, Huang M, Su Y, Zhang Y, Hu M, et al.
Cell Mol Gastroenterol Hepatol
. 2024 Oct;
19(2):101420.
PMID: 39414025
Background & Aims: The interactions between human milk and the regulation of innate immune homeostasis in newborns, and their impact on intestinal health, are not fully understood. This study aimed...
7.
Zhang L, Jin W, Hu M, Su Y, Zhang Y, Yuan F, et al.
Heliyon
. 2024 Sep;
10(17):e37087.
PMID: 39286078
Background: Necrotizing enterocolitis (NEC) is a condition characterized by acquired damage to the mucosal lining, predominantly affecting premature infants. Bioinformatics assessments uncovered a notable rise in miR-155-5p expression in the...
8.
Peng F, Hu M, Su Z, Hu L, Guo L, Yang K
Adv Mater
. 2024 Jul;
36(38):e2405331.
PMID: 39054925
In recent years, advancements in microbial sequencing technology have sparked an increasing interest in the bacteria residing within solid tumors and its distribution and functions in various tumors. Intratumoral bacteria...
9.
Bu C, Hu M, Su Y, Yuan F, Zhang Y, Xia J, et al.
J Cell Mol Med
. 2024 Jul;
28(14):e18534.
PMID: 39031467
Intestinal dysbiosis is believed to play a role in the development of necrotizing enterocolitis (NEC). The efficacy of JNK-inhibitory peptide (CPJIP) in treating NEC was assessed. Treatment with CPJIP led...
10.
Hu M, Deng F, Song X, Zhao H, Yan F
J Exp Clin Cancer Res
. 2024 Jul;
43(1):190.
PMID: 38987821
Pyroptosis is a cell death process characterized by cell swelling until membrane rupture and release of intracellular contents. As an effective tumor treatment strategy, inducing tumor cell pyroptosis has received...